Using pumpkin seed extract to improve blood sugar levels in people with subhealth
Effectiveness of Pumpkin Seed Extract on Improving Blood Sugar Level in Subhealth Subjects
NA · Greenyn Biotechnology Co., Ltd. · NCT05738655
This study is testing if pumpkin seed extract can help people with slightly elevated blood sugar levels manage their blood sugar better.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 20 Years to 75 Years |
| Sex | All |
| Sponsor | Greenyn Biotechnology Co., Ltd. (industry) |
| Locations | 1 site (Taipei) |
| Trial ID | NCT05738655 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of pumpkin seed extract in managing blood sugar levels among individuals classified as subhealthy. It employs a randomized, double-blind, placebo-controlled design, comparing low and high doses of the extract against a placebo. Participants will be monitored for changes in fasting blood sugar and glycated hemoglobin levels over the course of the study. The aim is to determine if pumpkin seed extract can provide a beneficial effect on blood sugar management.
Who should consider this trial
Good fit: Ideal candidates are individuals with fasting blood sugar levels between 100 to 125 mg/dL and glycated hemoglobin levels from 5.7 to 6.4%.
Not a fit: Patients with diagnosed type I or II diabetes, severe chronic diseases, or those with allergies to pumpkin seeds will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could offer a natural supplement option for improving blood sugar levels in individuals at risk of diabetes.
How similar studies have performed: While the specific use of pumpkin seed extract is novel, similar studies on natural supplements for blood sugar management have shown varying degrees of success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Fasting blood sugar levels from 100 to 125 mg/dL * Glycated hemoglobin levels from 5.7 to 6.4% * 2-hour OGTT levels from 140 to 199 mg/dL Exclusion Criteria: * Pregnant women or preparing for pregnancy. * Lactating women. * Women gave birth 6 months before the study. * Poor kindy funciton * Severe cardiovascular or other chronic diseases * Patients with type I or II diabetes * Poor compliance * Alcohol abuser * Using anti-diabetic or weight managent supplements * Blood transfusion three months before the study * Pumpkin seed allergy
Where this trial is running
Taipei
- WanFang Hospital — Taipei, Taiwan (RECRUITING)
Study contacts
- Principal investigator: Ming-Shun Wu, MD — WanFang Hospital
- Study coordinator: Ming-Shun Wu, MD
- Email: mswu@tmu.edu.tw
- Phone: +886-229307930
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Diabetes, Metabolic Disease